Exclusive

Publication

Byline

Location

Power, prisons and psychology: A look back at Stanford Prison Experiment that Netflix is recreating

India, Sept. 17 -- In 1887, the British historian Lord Acton wrote that "power tends to corrupt, and absolute power corrupts absolutely". For decades, an experiment held at Stanford University in 1971... Read More


Xi's open-source AI pitch: A reminder of why Delhi endorses a third way forward

India, Sept. 14 -- Chinese President Xi Jinping on Sunday proposed a Brics open-source artificial intelligence community, offering the grouping a Beijing-led alternative to the closed-model ecosystems... Read More


Bioweapons research, election meddling and a Yemen-based missile cell: the many misuse attempts on Claude

India, Sept. 11 -- Scientists working inside state-supported research programmes have used Anthropic's Claude models to help plan and write up experiments that could feed into biological weapons devel... Read More


The road to rogue AI, and the technical shortcut behind it

India, Sept. 10 -- Anthropic researcher Jacob Coxon resigned on Wednesday and wrote on X that AI companies were "racing straight to self-improving superintelligence and gambling with our lives". An ex... Read More


Miami plane crash: Why landing is one of aviation's most dangerous phases

India, Sept. 8 -- A Boeing 767 freighter carrying Amazon cargo touched down on runway 30 at Miami International Airport at about 1.58pm local time on Sunday, ran out of pavement, went through the peri... Read More


Nepal wants polluters to pay for floods: How strong is its case and climate justice today

India, Sept. 3 -- In a report published on August 28, Binod Parajuli set out what the satellite pictures showed about the origins of the August 26 tragedy. A senior divisional hydrologist in the flood... Read More


Rasonque gets US nod: The pill that nearly doubles pancreatic cancer survival - and is set to $475,000 a year

India, Aug. 27 -- The US has approved the first drug to hit the molecular cause of most pancreatic cancers, a once-daily pill that in its pivotal trial extended survival to 13.2 months from 6.7 months... Read More


Rasonque gets US nod: The pill that nearly doubles pancreatic cancer survival - and is set to cost $475,000 a year

India, Aug. 27 -- The US has approved the first drug to hit the molecular cause of most pancreatic cancers, a once-daily pill that in its pivotal trial extended survival to 13.2 months from 6.7 months... Read More


mRNA's second act: A bespoke cancer vaccine & what Merck-Moderna's melanoma trial could mean for oncology

India, Aug. 20 -- Merck and Moderna announced on Wednesday morning that a bespoke mRNA cancer vaccine, given alongside Merck's blockbuster immunotherapy Keytruda after surgery, significantly reduced d... Read More


mrna vaccinecuts recurrence of melanoma in crucial trial

New Delhi, Aug. 20 -- Merck and Moderna announced on Wednesday morning that a bespoke mRNA cancer vaccine, given alongside Merck's blockbuster immunotherapy Keytruda after surgery, significantly reduc... Read More